• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

药物洗脱支架真的物有所值吗？

Are drug eluting stents really worth the money?

作者信息

Thomas M

出版信息

Heart. 2006 Jan;92(1):5-7. doi: 10.1136/hrt.2005.066316. Epub 2005 Jun 6.

DOI:10.1136/hrt.2005.066316
PMID:15939723
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1860980/
Abstract

The cost effectiveness of drug eluting stents is being called into question. But is this fair in the light of all the available clinical data?

摘要

药物洗脱支架的成本效益正受到质疑。但根据所有现有的临床数据来看，这公平吗？

相似文献

1
Are drug eluting stents really worth the money?药物洗脱支架真的物有所值吗？
Heart. 2006 Jan;92(1):5-7. doi: 10.1136/hrt.2005.066316. Epub 2005 Jun 6.
2
Economics of sirolimus-eluting stents: drug-eluting stents have really arrived.西罗莫司洗脱支架的经济学：药物洗脱支架真的已经到来。
Circulation. 2004 Aug 3;110(5):472-4. doi: 10.1161/01.CIR.0000136820.77558.B1.
3
Cost effectiveness of drug eluting coronary artery stenting in a UK setting: cost-utility study.英国背景下药物洗脱冠状动脉支架置入术的成本效益：成本效用研究。
Heart. 2006 Jan;92(1):68-74. doi: 10.1136/hrt.2004.053850. Epub 2005 Apr 14.
4
Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial.西罗莫司洗脱支架治疗复杂冠状动脉狭窄的成本效益：来自西罗莫司洗脱球囊扩张支架治疗初发原发性冠状动脉病变患者（SIRIUS）试验的结果。
Circulation. 2004 Aug 3;110(5):508-14. doi: 10.1161/01.CIR.0000136821.99814.43. Epub 2004 Jul 19.
5
Drug-eluting stents: cost versus clinical benefit.药物洗脱支架：成本与临床效益对比
Circulation. 2003 Jun 24;107(24):3003-7. doi: 10.1161/01.CIR.0000078025.19258.28.
6
Drug-eluting stents: costs versus clinical benefit.药物洗脱支架：成本与临床效益对比
Circulation. 2003 Jun 24;107(24):3008-11. doi: 10.1161/01.CIR.0000079018.84618.0E.
7
Drug eluting stents: maximising benefit and minimising cost.药物洗脱支架：利益最大化与成本最小化
Heart. 2003 Feb;89(2):127-31. doi: 10.1136/heart.89.2.127.
8
Hippocrates revisited: the evidence for drug-eluting stents.
Circulation. 2003 Jun 24;107(24):3012-4. doi: 10.1161/01.CIR.0000079940.15982.75.
9
Can we afford to eliminate restenosis? Can we afford not to?我们能否承担消除再狭窄的代价？我们能否承担不这样做的代价？
J Am Coll Cardiol. 2004 Feb 18;43(4):513-8. doi: 10.1016/j.jacc.2003.11.020.
10
Drug-eluting stents substantially lower rate of restenosis.
Rep Med Guidel Outcomes Res. 2003 Oct 17;14(20):7-9.

引用本文的文献

1
Trends in hospital discharges, management and in-hospital mortality from acute myocardial infarction in Switzerland between 1998 and 2008.1998 年至 2008 年瑞士急性心肌梗死患者的住院出院、治疗方式和院内死亡率趋势。
BMC Public Health. 2013 Mar 25;13:270. doi: 10.1186/1471-2458-13-270.

本文引用的文献

1
Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial.糖尿病患者使用基于聚合物的紫杉醇洗脱TAXUS支架的疗效：TAXUS-IV试验
J Am Coll Cardiol. 2005 Apr 19;45(8):1172-9. doi: 10.1016/j.jacc.2004.10.075.
2
Cost effectiveness of drug eluting coronary artery stenting in a UK setting: cost-utility study.英国背景下药物洗脱冠状动脉支架置入术的成本效益：成本效用研究。
Heart. 2006 Jan;92(1):68-74. doi: 10.1136/hrt.2004.053850. Epub 2005 Apr 14.
3
One year cost effectiveness of sirolimus eluting stents compared with bare metal stents in the treatment of single native de novo coronary lesions: an analysis from the RAVEL trial.雷帕霉素洗脱支架与裸金属支架治疗单处原发性冠状动脉新发病变的一年成本效益：来自RAVEL试验的分析
Heart. 2005 Apr;91(4):507-12. doi: 10.1136/hrt.2004.034454.
4
Impact of obesity on revascularization and restenosis rates after bare-metal and drug-eluting stent implantation (from the TAXUS-IV trial).肥胖对裸金属支架和药物洗脱支架植入术后血管重建及再狭窄率的影响（来自TAXUS-IV试验）
Am J Cardiol. 2005 Mar 15;95(6):709-15. doi: 10.1016/j.amjcard.2004.11.020.
5
Economic evaluation of sirolimus-eluting stents.西罗莫司洗脱支架的经济学评估。
CMAJ. 2005 Feb 1;172(3):345-51. doi: 10.1503/cmaj.1041062.
6
Access to catheterisation facilities in patients admitted with acute coronary syndrome: multinational registry study.急性冠状动脉综合征入院患者使用导管插入设施的情况：多国注册研究
BMJ. 2005 Feb 26;330(7489):441. doi: 10.1136/bmj.38335.390718.82. Epub 2005 Jan 21.
7
Relationship of late loss in lumen diameter to coronary restenosis in sirolimus-eluting stents.西罗莫司洗脱支架管腔直径后期丢失与冠状动脉再狭窄的关系。
Circulation. 2005 Jan 25;111(3):321-7. doi: 10.1161/01.CIR.0000153356.72810.97. Epub 2005 Jan 17.
8
Predictive factors for ischemic target vessel revascularization in the Prevention of Restenosis with Tranilast and its Outcomes (PRESTO) trial.
J Am Coll Cardiol. 2005 Jan 18;45(2):198-203. doi: 10.1016/j.jacc.2004.05.089.
9
One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial.基于聚合物的缓释紫杉醇洗脱TAXUS支架的一年临床结果：TAXUS-IV试验
Circulation. 2004 Apr 27;109(16):1942-7. doi: 10.1161/01.CIR.0000127110.49192.72. Epub 2004 Apr 12.
10
Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis.西罗莫司洗脱支架与标准支架治疗冠状动脉再狭窄高危患者的随机对照试验（SIRIUS 试验）1 年临床结果分析
Circulation. 2004 Feb 10;109(5):634-40. doi: 10.1161/01.CIR.0000112572.57794.22.